Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Reactogenicity and Protectivity Following Measles- Rubella (MR) Routine Immunization in Indonesian Infants and Children

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03680417
Recruitment Status : Completed
First Posted : September 21, 2018
Last Update Posted : September 12, 2019
Sponsor:
Information provided by (Responsible Party):
PT Bio Farma

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
to assess safety and immunogenicity of measles-rubella (MR) routine immunization in Indonesian Children and Infants

Condition or disease Intervention/treatment Phase
Safety Issues Immunogenicity Biological: Measles-Rubella (MR) Vaccine Phase 4

Detailed Description:
  • to asses serious immediate systemic events,
  • to assess local and systemic reaction after Measles-Rubella (MR) vaccine in infants and children,
  • to evaluate protectivity and antibody response to measles and rubella after 1 dose of MR vaccine
Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 590 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: Safety Group: open labeled, prospective intervention study, only assess the safety outcome Sub Group: open labeled, prospective intervention study, evaluate safety and protectivity outcome
Masking: Single (Outcomes Assessor)
Masking Description: laboratory analyst are masked for the evaluation of antibody against measles and rubella. The immunogenicity is measured before and after vaccination.
Primary Purpose: Prevention
Official Title: Reactogenicity and Protectivity Following Measles- Rubella (MR) Routine Immunization in Indonesian Infants and Children
Actual Study Start Date : November 16, 2017
Actual Primary Completion Date : February 26, 2018
Actual Study Completion Date : August 1, 2018

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Measles Rubella

Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Active Comparator: Safety Study (Measles-Rubella vaccine)
open labeled, prospective intervention study, only assess the safety outcome. The Measles-Rubella vaccine is administered in infants age 9-12 months or 18 - 47 months. This study group only assessed for safety profile of the Measles-Rubella vaccine.
 Biological: Measles-Rubella (MR) Vaccine
Measles and Rubella Vaccine, live attenuated (Serum Institute of India) Form : Freeze dried Dose : 1 dose 0.5 ml contains not less than 1000 CCID50 of measles virus and 1000 CCID50 of rubella virus.
Active Comparator: Sub Study (Measles-Rubella vaccine)
open labeled, prospective intervention study, assess the safety and immunogenicity outcome. The Measles-Rubella vaccine is administered in infants age 9-12 months or 18 - 47 months. For Sub study, pre- and post immunization sera will be obtained from 200 infants and/or children. Safety assessment also evaluated for 28 days after immunization.
 Biological: Measles-Rubella (MR) Vaccine
Measles and Rubella Vaccine, live attenuated (Serum Institute of India) Form : Freeze dried Dose : 1 dose 0.5 ml contains not less than 1000 CCID50 of measles virus and 1000 CCID50 of rubella virus.


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Number of Immediate systemic events [ Time Frame: 30 minutes ]
    Number of subjects with at least one serious immediate systemic events within 30 minutes after vaccination

  2. Percentage of immediate systemic events [ Time Frame: 30 minutes ]
    Percentage of subjects with at least one serious immediate systemic events within 30 minutes after vaccination


Secondary Outcome Measures :
  1. Local reaction [ Time Frame: 72 hours ]
    Number of subjects with at least one local reaction occurring within 72 h after vaccination.

  2. Systemic reaction [ Time Frame: 72 hours ]
    Number of subjects with at least one systemic event occurring within 72 h after vaccination.

  3. Delayed Local reaction [ Time Frame: 11 days ]
    Number of subjects with at least one local reaction occurring between day 4-14 after vaccination.

  4. Delayed systemic event [ Time Frame: 11 days ]
    Number of subjects with at least one systemic event occurring between day 4-14 after vaccination.

  5. Late Local reaction [ Time Frame: 14 days ]
    -Number of subjects with at least one systemic event occurring between day 15 to 28 following vaccination.

  6. Late Safety (Systemic event) [ Time Frame: 14 days ]
    Number of subjects with at least one systemic event occurring between day 15 to 28 following vaccination.

  7. Safety (serious adverse event) [ Time Frame: 28 days ]
    - Number of serious adverse event occuring from inclusion until 28 days after immunization

  8. Immunogenicity for Measles (subject with anti measles titer ≥ 8 (1/dil)) [ Time Frame: 28 days ]
    - Percentage of subjects with anti measles titer ≥ 8 (1/dil), 28 days after one dose of MR vaccine in Infants & Children.

  9. Immunogenicity for Measles (Geometric Mean Titer) [ Time Frame: 28 days ]
    - Geometric Mean Titer of measles antibody

  10. Immunogenicity for Measles (increasing measles antibody titer ≥ 4 times) [ Time Frame: 28 days ]
    - Percentage of infants with increasing measles antibody titer ≥ 4 times

  11. Immunogenicity for Measles (seroconversion from seronegative to seropositive) [ Time Frame: 28 days ]
    - Percentage of infants with transition of seronegative to seropositive.

  12. Immunogenicity for Rubella (Subjects with anti rubella titer ≥11 IU/ml) [ Time Frame: 28 days ]
    - Percentage of subjects with anti rubella titer ≥11 IU/ml, 28 days after one dose of MR vaccine in Infants & Children.

  13. Immunogenicity for Rubella (Geometric Mean Titer) [ Time Frame: 28 days ]
    - Geometric Mean Titer of Rubella antibody.

  14. Immunogenicity for Rubella (increasing rubella antibody titer ≥ 4 times) [ Time Frame: 28 days ]
    - Percentage of infants with increasing rubella antibody titer ≥ 4 times

  15. Immunogenicity for Rubella (seroconversion from seronegative to seropositive) [ Time Frame: 28 days ]
    - Percentage of infants with transition of seronegative to seropositive.


Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   9 Months to 47 Months   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Healthy infants (9-12 months) or children (18-47 months)
  • Will receive MR routine immunization.
  • Parents have been informed properly regarding the study and signed the informed consent form.
  • Parents will commit themselves to comply with the instructions of the investigator and the schedule of the trial.

Exclusion Criteria:

  • MR vaccine given simultaneously with other vaccination, except Pentabio (DTP/HB/Hib)
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03680417


Locations
Layout table for location information
Indonesia
Child Health Dept. Dr. Soetomo Hospital, School of Medicine Airlangga Univ.
Surabaya, East Java, Indonesia, 60131
Sponsors and Collaborators
PT Bio Farma
Investigators
Layout table for investigator information
Principal Investigator: Dominicus Husada, Dr Child Health Dept. Dr. Soetomo Hospital/School of Medicine, Airlangga Univ.
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Layout table for additonal information
Responsible Party: PT Bio Farma
ClinicalTrials.gov Identifier: NCT03680417    
Other Study ID Numbers: PMS-MR-0417
First Posted: September 21, 2018    Key Record Dates
Last Update Posted: September 12, 2019
Last Verified: September 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by PT Bio Farma:
Measles-Rubella
Vaccine
Safety
 Immunogenicity
Reactogenicity
Protectivity
Additional relevant MeSH terms:
Layout table for MeSH terms
Measles
Rubella
Morbillivirus Infections
Paramyxoviridae Infections
Mononegavirales Infections
 RNA Virus Infections
Virus Diseases
Rubivirus Infections
Togaviridae Infections